Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.

Timothee BruelLou-Léna VrignaudFrançoise PorrotIsabelle StaropoliDelphine PlanasFlorence Guivel-BenhassineJulien PuechMatthieu ProtSandie MunierWilliam Henry-BollandCathia SouliéKaren ZafilazaClovis Lusivika-NzingaMarie-Laure MeledgeCéline DorivalDiana MolinoHélène PéréYouri YordanovEtienne Simon-LorièreDavid VeyerFabrice CarratOlivier SchwartzAnne-Geneviève MarcelinGuillaume Martin-Blondelnull null

Published in: medRxiv : the preprint server for health sciences (2023)

Our results show that sotrovimab is active against BQ.1.1 and XBB.1.5 in treated individuals, suggesting that it may be a valuable therapeutic option.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
patient reported